Back to results
US 2026/0028330 A1Published application
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
AssigneeLiminal Biosciences Limited
InventorsShaun Abbott, Mylène De Lèsèleuc, Julien Martel, ELYSE Bourque, Jeremy Green, Nadia Michel Nasser
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
Claims138
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom;
- or phenylene;
- each of which is substituted with m occurrences of R3;
- A2 is phenylene, a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 9-10 membered partially saturated carbocyclylene;
- each of which is substituted with n occurrences of R4;
- L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain wherein 1 methylene unit of the chain is optionally replaced with —O—;
- L2 is —C(O)N(R5)—, —N(R6)C(O)—, —N(R6)—, —N(R6)—(C1-4 alkylene)-, —(C1-4 alkylene)-N(R6)—, —S(O)2N(R5)—, —N(R6)S(O)2—, —CO2—, or —OC(O)—;
- R1 is —C(O)N(R7)(R8), a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- wherein each of said bicyclic heterocyclic ring and monocyclic heterocyclic ring are substituted with q instances of R9;
- R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl) or hydrogen;
- R3 represents independently for each occurrence C1-6 alkyl or halo;
- R4 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8);
- R5 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
- or R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom;
- R6 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
- R7 and R8 each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-6 cycloalkyl;
- or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom;
- R9 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, or C3-6 cycloalkyl;
- and
- m, n, and q are independently 0, 1, or 2;
- wherein if R1, L1, A1 and L2 taken together form
- then n is 1 or 2, and R4 represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8).
23 more elements
A compound in Table 1, or a pharmaceutically acceptable salt thereof.
A compound of Formula II:
- or a pharmaceutically acceptable salt thereof, wherein:
- A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom;
- or phenylene;
- each of which is substituted with m occurrences of R3;
- A2 is phenylene, a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 9-10 membered partially saturated carbocyclylene;
- each of which is substituted with n occurrences of R4;
- L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain wherein 1 methylene unit of the chain is optionally replaced with —O—;
- L2 is —C(O)N(R5)—, —N(R6)C(O)—, —N(R6)—, —N(R6)—(C1-4 alkylene)-, —(C1-4 alkylene)-N(R6)—, —S(O)2N(R5)—, —N(R6)S(O)2—, —CO2—, —OC(O)—, —C(O—C1-4 alkyl)=N—, or -(4-5 membered saturated monocyclic heterocyclylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur)-N(C1-4 alkyl)-;
- R1 is —C(O)N(R7)(R8), a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- wherein each of said bicyclic heterocyclic ring and monocyclic heterocyclic ring are substituted with q instances of R9;
- R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl) or hydrogen;
- R3 represents independently for each occurrence C1-6 alkyl or halo;
- R4 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8);
- R5 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
- or R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom;
- R6 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
- R7 and R8 each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-6 cycloalkyl;
- or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom;
- R9 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, or C3-6 cycloalkyl;
- and
- m, n, and q are independently 0, 1, or 2;
- wherein if R1, L1, A1 and L2 taken together form
- then n is 1 or 2, and R4 represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8).
23 more elements
A compound in Table 1A, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.